NousQ Pte Ltd Secures $7.5M in Series A Funding to Accelerate Patient-Centric Medical Innovation

NousQ Pte Ltd, a dynamic Singapore-based start-up that pivoted in July 2021 to focus on designing, developing, manufacturing, and commercialising innovative medical technology and devices, is thrilled to announce its latest funding milestone of USD 7.5 million. This sizeable investment not only underlines the strong confidence that stakeholders and investors have in NousQ’s mission, but also marks a pivotal step forward in its relentless pursuit to revolutionise patient-centric healthcare. Rooted in its commitment to developing solutions that patients truly need, NousQ continues to drive innovation aimed at optimising healthcare delivery for the current population while actively addressing the needs of the millions who currently lack access to quality care. This significant capital infusion will be strategically channelled towards accelerating research and development, enhancing manufacturing capabilities, and expanding clinical trials, including the eagerly anticipated first-in-man pilot clinical trial for its revolutionary Clikx device scheduled to commence in 2022 in Singapore. By partnering with valued stakeholders across the healthcare ecosystem, NousQ is not only building a robust and sustainable enterprise but also giving hope to patients around the globe. The company’s forward-thinking approach and dedication to bridging the gap between advanced medical technology and patient needs ensure that this latest funding round will have a far-reaching impact on both existing and underserved patient populations. As NousQ continues to pioneer groundbreaking solutions, this latest achievement reinforces its role as a beacon of innovation in the medical technology arena, poised to transform healthcare delivery and set new benchmarks for patient care worldwide.